Summary
The concentrations of cinepazide in human plasma and urine were studied by using high-performance liquid chromatography. Each of 7 healthy , male volunteers received 200 and 400 mg of cinepazide on separate occasions for single dose experiments. In the case of the 200 mg single dose , a rapid peak of plasma conwas excreted in urine within 24 hr. The peak plasma level increased proportionally with the dose of cinepazide, whereas the extent of cinepazide excretion increased slightly with the dose.
In multiple dose experiments, each of these volunteers received, on two separate occasions, 200 mg of cinepazide t. i. d. at 9:00 am, 1:00 pm and 5:00 pm each day for 1 day and 5 days, respectively. Cinepazide, 4-(3, 4, 5-trimethoxycinnamoyl) -1 -(1 -pyrrolidinyl) carbonylmethylpiperazine maleate was developed by Delalande Co., Ltd.
(France) as a vasodilator (Pourrias, B. et al., 1974a , Pourrias, B. et al., 1974b , Marmo, E. et al., 1973 . The chemical structure is shown in Fig. 1 . The compound was found to be the most active vasodilator of several substituted cinnamoylpiperazines (Fauran, C. et al., 1969 , Huguet, G. et al., 1969 . The drug has been used to treat peripheral and cerebral vascular disorders (Bremer, C., 1974 , Garrigues, A., 1975 A similar protocol was followed when cine- pazide was administered t. i. d. for 5 days (Step 4). Heparinized plasma specimens were obtained at 0, 1.5, 8 and 9.5 hr after the first administration of the drug on days 1, 2, 3, and 4.
Samples were taken at 0, 1.5, 8, 9.5, 10 and 11 hr on day 5 and at 0 and 8 hr on day 6. Total urine was collected every 24 hr for 5 days, and then until analysis.
Analytical methods

Sample preparation
Plasma : To a 50 ml glass stoppered centrifuge tube were added 1.0 ml of plasma and 1 ml Table 3 .
5, Pharmacokinetic Analysis
The plasma level versus time profile for cinepazide could be described adequately by viewing the body as consisting of one compartment, with the drug being absorbed, distributed and eliminated from the body through a series of first-order process. Fitting a double-expo- 
Results
Cinepazide was administered in single 200 or 400 mg oral doses. The peak concentration was obtained at 1-3 hr and averaged 3.7 (range 2.8 (Table 4, Table 5 ). Interindividual variation in plasma level was rather large at 0.5-1 hr after drug ingestion. The peak plasma level increased proportionally with the dose of cinepazide.
Next, there was a rapid fall in the plasma level at both dose levels. The biological half-life varied from subject to subject over the range 0.9-2.7 hr and was independent of the dose, as shown in Table 6 . The plasma levels were not measurable by The individual plasma levels at 7 : 00 pm (2 hr was slightly higher than the peak plasma level after a single oral dose of 200 mg of cinepazide.
At 24 hr after the final dose, the plasma cine pazide levels were nearly zero. Table 7 
